Extended-release trospium chloride improves quality of life in overactive bladder.
OBJECTIVE
Overactive bladder syndrome (OAB) is a urinary condition that often exerts detrimental effects on an individual's quality of life (QoL). A once-daily, extended-release (ER) formulation of the quaternary amine trospium chloride has recently been developed for the treatment of OAB. The pooled health-related QoL (HRQoL) data from two multicenter, parallel-group, double-blind Phase III studies with trospium chloride ER 60 mg were analyzed.


METHODS
Subjects aged>or=18 years with urinary urgency, frequency, and an average of >or=1 urge urinary incontinence episode per day on a 3-day bladder diary were randomized (1:1) to receive once-daily trospium 60 mg ER or placebo for 12 weeks. HRQoL was assessed at baseline and at Week 12 using the King's Health Questionnaire (KHQ) and the OAB questionnaire (OAB-q).


RESULTS
Overall, 1165 subjects were randomized (trospium ER, n=578; placebo, n=587). Trospium ER produced significantly greater improvements from baseline than placebo in seven of the nine KHQ domains. At Week 12, the improvement in mean OAB-q HRQoL total score (from approximately 52 at baseline) was significantly greater with trospium ER than with placebo (+25.8 vs. +20.7; P=0.0003). Improvements from baseline were seen with trospium ER on all eight of the OAB-q symptom bother scales.


CONCLUSIONS
Once-daily trospium 60 mg ER improved the QoL of subjects with OAB, as assessed using the KHQ and the OAB-q, in two large Phase III clinical trials.
Dmochowski
Roger R
RR
Department of Urology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. roger.dmochowski@vanderbilt.edu
Rosenberg
Matt T
MT
Zinner
Norm R
NR
Staskin
David R
DR
Sand
Peter K
PK
D001561:Benzilates; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009662:Nortropanes / Q000008:administration & dosage*; D010276:Parasympatholytics / Q000008:administration & dosage*; D011788:Quality of Life; D018434:Sickness Impact Profile; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000523:psychology
D001561:Benzilates; D003692:Delayed-Action Preparations; D009662:Nortropanes; D010276:Parasympatholytics; C003330:trospium chloride